MarketMoodz
Elliott Sees Billions Hidden Inside Bio‑Rad Laboratories
Elliott Investment Management has built a sizable stake in Bio‑Rad Laboratories and is pressing a thesis that the company sits on hidden value — notably a large stake in Sartorius that Elliott reportedly values at about $5 billion. That opportunity comes as Bio‑Rad struggles with weaker margins, a trimmed 2026 revenue guide and shares down more than 70% from their 2021 peak, while family voting control could limit activist leverage.
Key Takeaways
- Elliott has built a sizable stake in Bio‑Rad and reportedly values Bio‑Rad’s Sartorius stake at roughly $5 billion (reporting based on unnamed sources).
- Bio‑Rad’s market value is about $6.6 billion and shares are down over 70% from a 2021 pandemic-era high above $800.
- Q1 2026 adjusted EPS was $1.89 (consensus $1.98) and sales were $592.1 million (consensus $588.9 million).
- Bio‑Rad trimmed 2026 revenue guidance to $2.51–$2.59 billion versus consensus $2.63 billion and guided operating margins of 10–12%, well below peers above 30%.
- The Bio‑Rad founding family retains majority voting control, which the Wall Street Journal says could complicate activist-driven governance changes.
People Involved
- Bio‑Rad founding familyholders of majority voting control
Entities Involved
- Elliott Investment Managementactivist investor that built a sizable stake in Bio‑Rad
- Bio‑Rad Laboratories (BIO)life‑science tools and diagnostics company; issuer of Q1 2026 results and 2026 guidance
- Sartoriuspublic life‑science supplier in which Bio‑Rad holds a material stake reportedly valued by Elliott at ~$5 billion
- The Wall Street Journalreported that founder‑family control could complicate governance‑driven activism
MarketMoodz Analysis
For investors this is a classic activist value case: a company with a depressed market cap (~$6.6 billion), a potentially monetizable equity stake (Sartorius) and operational underperformance that has driven shares down more than 70% from the 2021 peak. Bio‑Rad’s Q1 2026 miss on adjusted EPS ($1.89 versus $1.98 consensus) alongside a revenue beat ($592.1 million versus $588.9 million) and a trimmed full‑year revenue guide ($2.51–$2.59 billion versus $2.63 billion consensus) show uneven execution. The 10–12% operating margin guidance — versus peer margins north of 30% — highlights scope for either operational improvement or value unlocking via capital‑allocation moves such as divestitures, buybacks or a strategic sale of assets.
That upside is tempered by governance. The founding family’s majority voting control, flagged by the Wall Street Journal, raises the bar for an Elliott‑led overhaul: proxy fights are harder, board contests less certain and friendly negotiations more likely. Also note that the ~$5 billion valuation of the Sartorius stake is reported by unnamed sources and hasn’t been independently verified, so investors should treat the figure as a potential—not guaranteed—source of value. What to watch next: management’s response in the upcoming earnings cycle, any board disclosures about strategic reviews or capital returns, moves to monetize the Sartorius position, and whether improving biopharma R&D trends and dealmaking in diagnostics translate into higher revenue and margin leverage for Bio‑Rad.
Source: Original Article